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Recent studies reported that many different biochemical forms of B-type-
related peptides circulate in human blood. In particular, a significant amount
of the prohormone peptide (i.e., proBNP108) can be detected in plasma of
patients with heart failure. These data indicate that the posttranslational
maturation processing of the B-type natriuretic peptide (BNP) precursor
may not be efficient in heart failure. The aim of this chapter is to describe
the biochemical pathways of proBNP108 maturation and to discuss the
pathophysiological relevance of alteration of the posttranslational matura-
tion mechanisms in heart failure. An impaired cardiac endocrine function
was proposed to explain the altered electrolyte and fluid homeostasisInc.
rved.
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Author's personal copyoccurring in chronic heart failure. Recent studies demonstrated that a great
part of BNPs assayed by immunoassay methods in healthy subjects and in
patients with cardiovascular disease is devoid of biological activity. These
findings suggest that an alteration in posttranslational maturation of BNP
precursor may promote the resistance to biological action of BNP in
patients with heart failure at a prereceptor level. These studies also open a
new and more complex scenario regarding the circulating BNPs. The active
hormone (i.e., BNP1–32) may be produced even in vivo from the circulating
precursor proBNP108 by plasma enzyme degradation, such as the soluble
form of corin, possibly able to process the circulating intact precursor of
natriuretic hormones. As a future perspective, the simultaneous measure-
ment of the proBNP1–108 and the active peptide BNP1–32 with more specific
methods could allow a more accurate estimation of both production/secre-
tion of B-type-related peptides from cardiomyocytes and the true activity of
the cardiac endocrine function.2. Background and Aim of the Study
All natriuretic peptides (including atrial natriuretic peptide (ANP), BNP,
and C-type natriuretic peptide (CNP)) share a direct diuretic, natriuretic, and
vasodilator effect as well as an inhibitory action on the inflammatory pro-
cesses of both myocardium and smooth muscle cells [1–3]. Natriuretic pep-
tides exert a protective effect on endothelial function and vascular
remodeling [4–6]. These effects are mediated by two different guanylate
cyclase-coupled receptors, NPR-A (more specific for ANP and BNP) and
NPR-B (more specific for CNP)[7], while a third specific receptor NPR-C,
not coupled to a guanylate cyclase, has essentially a clearance function for all
natriuretic peptides [2,8].
A blunted natriuretic response after pharmacological doses of ANP and
BNP has been observed in experimental animal models and in patients with
chronic heart failure, suggesting a resistance to the biological effects of
cardiac natriuretic hormones CNH [9–11]. As discussed in detail elsewhere
[2,12,13], resistance to the biological action of CNH can be attributed at
least to three different causes/mechanisms, acting at prereceptor, receptor,
and postreceptor level, respectively (Table 1).
Several studies recently reported that many different biochemical forms of
B-type-related peptides circulate in human blood [14–34]. In particular, large
amounts of the BNP prohormone (i.e., proBNP108) can be detected in plasma
of patients with heart failure [14–21,24,31]. Dries et al. [21], using a specific
immunometric assay [17], found detectable levels of proBNP108 in the
99% of a large population of patients with chronic heart failure (i.e., 756
TABLE 1
CLASSIFICATION OF POSSIBLE MECHANISMS OF RESISTANCE TO BIOLOGICAL EFFECTS OF CNH
Pre-receptor level
(A) Presence of inactive peptides in plasma
(B) Increase in inactivation/degradation of active peptides
1. Upregulation of NPR-C
2. Increased activity of proteases
(C) Decreased renal filtration
Receptor level
(A) Downregulation of NPR-A and NPR-B in target tissues
(B) Altered CNH receptor binding or desensitization
Post-receptor level (activated counterregulatory mechanisms)
Altered intracellular signaling
1. Decreased cGMP cellular accumulation (decreased production or increased
degradation)
2. Altered intracellular pathways downstream cGMP
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processing of BNP precursor is not efficient in heart failure [15,20,22,31–33].
As a result, a great part of BNPs assayed in healthy subjects and patients with
cardiovascular disease may be devoid of biological activity. These findings
indicate that an alteration in posttranslational maturation processing
mechanisms of BNP precursor may promote the resistance to the biological
action of BNP in patients with heart failure at the prereceptor level
[2,22,32,33]. The aim of this chapter is to describe the biochemical pathways
of proBNP108 maturation and to discuss the pathophysiological relevance of
alteration of these posttranslational maturation mechanisms in heart failure.3. Biosynthesis of B-Type Natriuretic Peptides
in Cardiomyocytes
In humans, BNP is synthesized as a 134-amino acid (aa) precursor protein
(preproBNP) and is subsequently processed to form a 108-aa propeptide,
named proBNP1–108. The propeptide hormones of the cardiac natriuretic
peptides can be enzymatically cleaved by proprotein convertases produced
in the cardiomyocyte [32,35]. A cardiac serine protease, corin, and a ubiqui-
tous serine protease, furin, have been proposed as possible convertases
for proBNP1–108 [36–38]. These proteases convert the proBNP1–108 into the
76-aa N-terminal peptide (i.e., NT-proBNP1–76) and the biologically active
32-aa C-terminal peptide (i.e., BNP1–32) (Fig. 1).
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FIG. 1. Schematic representation of biosynthesis, secretion, and distribution of B-type-related
natriuretic peptides. Some of the biosynthesized prohormone (proBNP-108) is O-glycosylated
within the Golgi apparatus. If O-glycosylation does not occur, proBNP-108 can be cleaved
to BNP-32 and NT-proBNP-76 by the processing enzymes within the trans-Golgi network.
If O-glycosylation occurs, glycosylated-proBNP-108 cannot be cleaved, and uncleaved
glycosylated-proBNP-108 is secreted into the circulation. Finally, a smaller part of intact
prohormone is not glycosylated and cleaved, and so this peptide can be present into circulation
in intact form as proBNP-108. As indicated in the figure, the glycosylation on the threonyl
residue in position 71 (Thr 71) could regulate prohormone cleavage by either blocking or guiding
endoproteolytical enzymes. Only BNP1–32, which is the active hormone, is able to bind the
specific receptors, NPR-A and NPR-C. NPR-A is a guanylate cyclase-coupled receptor, which
mediates the biological effects of cardiac natriuretic peptides. NPR-C, not coupled to a guanylate
cyclase, has essentially a clearance function for all natriuretic peptides.
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Author's personal copyBiosynthesized prohormonemay be (or not)O-glycosylatedwithin theGolgi
apparatus; as a result, different maturation processing pathways are possible
for proBNP1–108 in cardiomyocytes [32,35,39] (Fig. 1). If O-glycosylation does
not occur, proBNP1–108 can be cleaved to BNP77–108 and NT-proBNP1–76 by
the processing enzymes within the trans-Golgi network. If O-glycosylation
occurs, glycosylated proBNP1–108 cannot be cleaved, and uncleaved glycosy-
lated proBNP1–108 is secreted into the circulation. Finally, a smaller part of
intact prohormone is not glycosylated and cleaved, and so this peptide can
be secreted into circulation in intact form as proBNP1–108. As indicated in
Fig. 1, the glycosylation on the threonyl residue in position 71 (Thr 71) may
regulate prohormone cleavage by either blocking or guiding endoproteolytic
enzymes [32,35]. A very recent study [39] suggested that the predominant
intracellular form of BNP was nonglycosylated proBNP1–108, rather than
BNP1–32. Glycosylated proBNP1–108, but not nonglycosylated proBNP1–108,
was detected as the major extracellular form in the culture supernatants of
preproBNP-expressing cell lines and primary human cardiomyocytes. Finally,
ablation of O-glycosylation of proBNP1–108 at T71 residue, near the convertase
recognition site, reduced the extracellular proBNP1–108 and increased extracel-
lular BNP1–32 [39], suggesting that glycosylation in this point may act as
regulatory site for precursor maturation.4. Circulating B-Type-Related Peptides:
Biochemical Characteristics
Some recent studies completely revised our vision concerning the biochemi-
cal characteristics of circulating forms of the B-type-related peptides. Only 5
years ago, the prohormones (i.e., proANP and proBNP) were thought to be
predominantly stored in secretory granules and then nearly completely split in
equimolar amounts into longer amino-terminal fragments (i.e., NT-proANP
and NT-proBNP) and shorter C-terminal active peptide hormones (i.e., ANP
and BNP) before secretion in the blood of healthy subjects [2,40]. On the
contrary, some recent evidences suggested that proBNP1–108 is the predomi-
nant B-type immunoreactive form in human blood of both the healthy subjects
and the patients with congestive heart failure [17,18,21,24,31,39,41].
According to the biosynthetic pathways described in the previous paragraph,
a huge number of circulating proBNP-derived fragments can be identified by
chromatographic procedures in plasma of experimental animals and patients
with heart failure [3,14–32,41,42]. Moreover, the proBNP1–108 and NT-
proBNP1–76 (and probably also other shorter peptides derived from these pep-
tides) are present in plasma in both glycosylated and nonglycosylated form,
especially in plasma samples of patients with heart failure [19,22,28,30–32,39].
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endogenous NT-proBNP1–76 contains a small portion (about 5%) of nonglyco-
sylated or incompletely glycosylated peptide and that this portion can be
detected by antibodies specific to the central part of the molecule.
A still open question is whether the circulating proBNP1–108 is also present
in polymeric form, such as trimer [25,26], or not [19]. Some more recent
studies indicate that the high molecular forms of proBNP1–108, found in older
studies, were more probably due to highly glycosylated forms of the precur-
sor peptide rather than due to the polymerization forms of the peptide [19].5. The Measurement of Different Circulating Forms of the
B-Type-Related Natriuretic Peptides: Analytical Characteristics
and Methodologic Challenges
The presence of many circulating molecular forms of B-type-related pep-
tides raises a question concerning the specificity of the immunoassay meth-
ods so far utilized for the routine measurement of these peptides in the
clinical practice [43–45]. Indeed, as hypothesized several years ago [43], all
immunoassays, which were considered specific for BNP1–32 or NT-proBNP1–76,
actually show a variable degree of cross-reactivity with proBNP1–108[44].
This issue actually raises a demanding methodological challenge [45]: the
search for more specific immunoassay methods not only for the biologically
active peptide BNP1–32 but also for all the other B-type-related peptides,
including the precursor proBNP1–108.
Some different methodological approaches have been recently considered for
themeasurement of proBNP1–108 [43]. In plasma or tissue extracts, proBNP1–108
was usually isolated by means of chromatographic procedures, in particular,
by HPLC, and then identified and measured by immunoassay or more accu-
rately by mass spectrometry [14–32,39,43]. These methods are not only highly
specific but also complex, time consuming, and not feasible for the clinical
laboratory routine [43]. To solve these problems, at least three different meth-
odological approaches have beendevelopedwith the aim to set uphighly specific
immunoassay methods for the measurement of proBNP1–108 [17,23,46].
Goetze et al. [23] set up a RIA for proBNP1–108 assay based on the measure-
ment of plasma treated with trypsin, which cleaves all proBNP-related peptides
to the small 1–21 fragment. The aim of these authors was to develop a proces-
sing-independent analysis for accurate quantification of proBNP1–108 and its
fragments in plasma. This method uses an antibody specific for a processing-
independent epitope of human proBNP1–108. This antibody was directed
against the first 10 aa of proBNP peptide, and the same peptide, radio-
iodinatedwith chloramine-T, was used as tracer in theRIA.Using thismethod,
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products in healthy volunteers and HF patients, showing that proBNP1–108
values were greatly higher in patients [23]. However, this RIA cannot be
recommended for the clinical practice since it requires a preliminary treatment
of plasma samples with trypsin, a very long incubation time (i.e., up to 5 days),
and the use of radiolabeled material. Further, it is theoretically conceivable
that this RIA measures all the peptides containing the N-terminal part of the
precursor proBNP1–108, including the NT-proBNP1–76. As a consequence, for
an accurate assayof circulating levels of the intact proBNP1–108,NT-proBNP1–76
concentration should be also accurately and independently measured.
Tamm et al. [46] developed a sandwich immunofluorescence assay for the
quantification of BNP1–32 and its precursor proBNP1–108. Authors reported
that this immunofluorescence assay holds a similar efficiency in recognizing
the BNP, as well as the recombinant glycosylated and nonglycosylated forms
of proBNP1–108 [46]. This immunoassay method (named ‘‘single-epitope
sandwich assay’’) is different from the conventional sandwich assay, requir-
ing only one epitope for antigen immunodetection by two different mono-
clonal antibodies. In this novel immunoassay, the first antibody is used as a
capture antibody and is specific for the region consisting of BNP amino acid
residues 11–22, which is the most stable part of the peptide and includes the
biologically active cysteine ring. The second antibody is used as a detection
antibody and recognizes the immune complex, including the antigen (i.e.,
BNP11–22) bound to the first antibody. In other words, the second antibody
does not recognize the free antigen, but the primary immune complex,
consisting of the first antibody and BNP1–32, operates as antigen for the
second antibody. Also this immunoassay method is not theoretically specific
for the intact proBNP1–108 peptide. Indeed, the single-epitope sandwich assay
should also recognize all the peptides (even shorter than proBNP1–108),
sharing the region consisting of amino acid residues 11–22 of BNP1–32 able
to form a complex with the first antibody.
Giuliani et al. [17] selected a specific monoclonal antibody (named ‘‘mAb
Hinge76’’) that recognizes the cleavage site of proBNP1–108, an epitope found
only in the precursor form (see Fig. 1). This monoclonal antibody recognizes
the recombinant proBNP1–108 in a dose-dependent manner, without any
significant cross-reactivity with either recombinant NT-proBNP1–76 or syn-
thetic BNP1–32. These authors set up a sandwich immunoassay for the
measurement of proBNP, by combining the monoclonal antibody mAb
Hinge76 with a polyclonal antibody directed against BNP1–32 (i.e., against
the COOH-terminal of proBNP1–108). An automated version of this method
on the BioPlexTM 2200 analyzer was then set up, and their analytical char-
acteristics have been evaluated [47]. More recently, some studies reported the
clinical results obtained with this immunoassay in the general population [25]
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Author's personal copyand in patients with heart failure [48] or chronic renal disease [49] by measur-
ing proBNP concentrations with this immunoassay method.
The setup of direct (i.e., without preliminary chromatographic purifica-
tion) accurate immunoassay methods for the biologically active cardiac
hormones, ANP and BNP, is recognized to be as a very challenging task,
due to the low plasma concentration, molecular weight, and plasma half-life
(both in vivo and in vitro) of these hormones, as compared to their hormone
precursors proANP and proBNP peptides (Table 2) [43]. Considering these
technical drawbacks, it is not surprising that all commercial immunoassay
methods, used in clinical routine and usually considered specific for BNP1–32,
are significantly interfered by the precursor peptide proBNP, although with
different degree of cross-reactivity [44].6. Pathophysiological Relevance of Circulating proBNP
The measurement of B-type-related peptides has attracted the attention of
clinicians when the pivotal role of cardiac endocrine function in the patho-
physiology of heart failure was established [2,8,20,22,33,40,50]. Further, the
introduction of the assay of B-type-related natriuretic peptides in clinical
practice has resulted in a significant improvement in accuracy of the diagnostic
and prognostic stratification workup in patients with cardiac diseases [50–57].
A deficient biological action of cardiac endocrine hormones has been
proposed to explain the altered electrolyte and fluid balance occurring in
chronic heart failure [2,11,13]. This phenomenon, defined as the ‘‘endocrine
paradox’’ of the heart [15,22], is characterized by extremely high circulating
levels of hormones, produced by cardiomyocytes, with powerful diuretic/
natriuretic and vasodilator activity in patients with congestive heart failure,
showing signs of fluid retention and vasoconstriction. As discussed in detailTABLE 2
BIOCHEMICAL AND PHYSIOLOGICAL CHARACTERISTICS OF BNP, NT-PROBNP, AND PROBNP PEPTIDES
BNP NT-proBNP proBNP
Molecular mass 3462 Da 8457 Daa 11,900 Daa
Amino acids 32 76 108
Biological
function
Active hormone Inactive Prohormone
Half-life 15–20 min >60 min >60 min
Glycosylation Not glycosylated Highly glycosylated in vivo Highly glycosylated in vivo
aThe molecular mass (MM) of NT-proBNP and proBNP depends on the degree of glycosyla-
tion of the peptide; in the table are reported the MM of nonglycosylated peptides.
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hormone system can be attributed to different mechanisms, acting at pre-
receptor, receptor, and/or postreceptor level (Table 1).
Considering the possible causes of resistance at the prereceptor level,
recent issues suggested that in patients with heart failure, there may be an
inadequate posttranslation maturation of the biosynthetic precursors of
BNP system [15,22,25–31,39]. Several studies indicated that a great part
of BNPs measured in patients with heart failure is devoid of biological
activity [15,16,20,30,36,38,39,59–61]. In addition to bioactive BNP1–32,
a huge number of circulating proBNP-derived fragments can be identified
by chromatographic procedures in human plasma, including the intact and
glycosylated forms of precursor proBNP1–108 and N-terminal truncated
BNP form 3–32 [15,22,25–31,39]. As compared to inactive peptides
proBNP1–108 and NT-proBNP, the active peptide BNP1–32 has a shorter
plasma half-life (about 15–20 min vs. 1 or 2 h) and consequently lower
plasma concentration (Table 2).
On the other hand, the above reported studies [15,16,20,30,31,36,38,39,59–61]
openalso a newandmore complex scenario regarding the circulatingBNPs.The
active hormone (i.e., BNP1–32) may be produced also in vivo from the circulating
precursor proBNP108 by plasma enzyme degradation [16–32,43–45,59–61].
Human blood contains a soluble form of corin, possibly able to process the
circulating intact precursor of natriuretic hormones [61,62]. In particular,
Dong et al. [61] recently reported that soluble corin is measurable in human
blood and that plasma corin levels are significantly lower in heart failure
patients than in healthy controls, and inversely correlated to the severity of
the disease [61]. Finally, Semenov et al. demonstrated that synthetic or
recombinant human proBNP can be processed to active BNP in the circulat-
ing blood, when injected in the femoral vein of rats [63]. The hypothesis of
the peripheral processing of circulating proBNP1–108 clearly assumes that
the peripheral maturation of the precursor proBNP1–108 would be submitted
to regulatory rules, possibly altered with heart failure progression
[16,20,22,32,48,59]. However, further studies are needed to clarify the patho-
physiological and clinical relevance of alteration in maturation of prohormone
precursors of cardiac natriuretic hormones in patients with heart failure.7. The Need of More Specific Immunoassays for the
Measurement of proBNP1–108 and BNP1–32 Peptides
The results of the CardioOrmocheck study [64] recently confirmed that the
most popular BNP immunoassays are affected by large systematic differ-
ences (up to 2.7 folds), while the agreement between NT-proBNP methods,
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(up to 1.2 folds). In particular, this multicenter proficiency testing study
reported that AxSYM and ARCHITET platforms (Abbott Diagnostics),
ACCESS and UniCell Dxi platforms (Beckman Coulter Inc.), and the
POCT method (TRIAGE Biosite, Inverness Medical) shared on average
similar BNP values, while the fully automated ADVIA Centaur platform
and an IRMA method (by Shionogi & Co., Ltd.,), which use the same anti-
bodies, showed on average significantly lower (of about 50%) results compared
with the other methods. Moreover, Luckenbill et al. [44] reported that there
are significant differences in cross-reactivity between proBNP1–108 and com-
mercially available BNP and NT-proBNP immunoassays. These data [44,63]
suggest that the large variation in BNP values measured by commercial
methods is largely due to differences in cross-reactivity with proBNP1–108
and its split products. On the other hand, a very recent study by Nishikimi
et al. [65] suggested that most endogenous plasma NT-proBNP1–76 is glycosy-
lated and undetectable with commercially available assay tests (i.e., ECLIA
method for fully automated platforms by Roche Diagnostics), which are not
able to detect the glycosylated peptide [44], and that the relative glycosylation
level is increased by hemodialysis in patients with chronic renal failure.
Therefore, the above-mentioned studies [44,64,65] clearly demonstrate that
commercial methods, considered specific for BNP1–32 and NT-proBNP1–76,
are actually not specific for these peptides. Since only BNP1–32 is believed to be
biologically active, at the present time, the commercially available assays
cannot accurately estimate the true biological activity of the cardiac natriuretic
system. In other words, there is a substantial discrepancy between biological
and immunological activities when commercial methods are employed for the
determination of plasma BNP concentration.
A fully automated immunoassay specific for proBNP1–108 has some theo-
retical advantages as biomarker (i.e., more stable molecule, higher molecular
weight, lower biologic variability) compared to the measurement of the
active hormone BNP (Table 2). As a future perspective, the simultaneous
measurement within the same plasma sample with two methods, one specific
for the intact precursor proBNP1–108 and the other for active peptide BNP1–32,
could allow a more accurate estimation of both production/secretion of
B-type-related peptides from cardiomyocytes and the true activity of the
cardiac endocrine function, compared to the single assay of either peptide.
Information obtained by simultaneous measurement of proBNP and BNP
with specific assays should likely extend our present knowledge of patho-
physiological mechanisms linking together heart failure progression and
cardiac endocrine dysfunction [33]. Indeed, a recent study in ambulatory
patients with chronic systolic heart failure showed that the combined assess-
ment of conventional BNP and proBNP immunoassays provides additional
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in patients with low BNP values [21]. However, other studies are needed to
definitively demonstrate the clinical usefulness of this new immunoassay [17]
for proBNP1–108 measurement.
In conclusion, more specific methods for the measurement of both
proBNP1–108 and BNP1–32 peptides are welcome in order to achieve a more
complete and accurate estimate of cardiac endocrine function. Further,
designed studies will be necessary to evaluate if these new specific assays
for BNP1–32 and proBNP1–108, used either alone or in combination, will
perform better in terms of diagnostic and prognostic accuracy as compared
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